Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
August 31, 2022 10:12 ET
|
BioNTech SE
Authorization based on clinical, pre-clinical and manufacturing data for Omicron-adapted bivalent vaccinesPfizer-BioNTech Omicron BA.4/BA.5 bivalent vaccine combines 15-µg of mRNA encoding the...
Pfizer und BioNTech reichen Antrag für Notfallzulassung eines angepassten bivalenten COVID-19-Impfstoffs für Omikron-Varianten BA.4/BA.5 bei der FDA ein
August 22, 2022 10:30 ET
|
BioNTech SE
Die Daten stützen Antrag auf Notfallzulassung einer 30-µg-Auffrischungsdosis eines an Omikron BA.4/BA.5 angepassten bivalenten COVID-19-Impfstoffs für Personen ab 12 JahrenDie Unternehmen haben die...
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
August 22, 2022 10:30 ET
|
BioNTech SE
Data support request for Emergency Use Authorization of a 30-µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and olderCompanies have rapidly...
Pfizer und BioNTech erhalten FDA-Notfallzulassung für ihren COVID-19-Impfstoff bei Kindern im Alter von 6 Monaten bis 4 Jahren
June 17, 2022 09:22 ET
|
BioNTech SE
Daten einer klinischen Phase-2/3-Studie zeigten, dass der Pfizer-BioNTech COVID-19-Impfstoff in dieser Altersgruppe eine starke Immunantwort auslöstDie Impfserie mit drei 3-µg-Dosen bei Kindern im...
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
June 17, 2022 09:22 ET
|
BioNTech SE
In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile similar to placebo in young...
NRXP DEADLINE TODAY: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages NRx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important March 21 Deadline in Securities Class Action – NRXP, NRXPW
March 21, 2022 10:57 ET
|
The Rosen Law Firm PA
NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP, NRXPW) between...
AXIM Biotech Launches For Research Use Only Sales for its COVID-19 Neutralizing Antibody Test
March 07, 2022 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye...
NATIONALLY RANKED ROSEN LAW FIRM Encourages Talis Biomedical Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – TLIS
January 14, 2022 15:35 ET
|
The Rosen Law Firm PA
NEW YORK, Jan. 14, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
Pfizer und BioNTech erhalten U.S.-Notfallzulassung für COVID-19-Auffrischungsimpfung bei Personen ab 16 Jahren durch die FDA
December 09, 2021 12:15 ET
|
BioNTech SE
Dies ist die erste Notfallzulassung (Emergency Use Authorization, „EUA”) für eine COVID-19-Auffrischungsimpfung bei Personen ab 16 Jahren in den Vereinigten Staaten NEW YORK, USA und MAINZ,...
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older
December 09, 2021 12:15 ET
|
BioNTech SE
First emergency use authorization in the United States for a COVID-19 vaccine booster in individuals 16 years and older NEW YORK and MAINZ, Germany, December 9, 2021 — Pfizer Inc. (NYSE: PFE) and...